21 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
24405703	72	4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.	Janssen Research and Development
24153205	21	4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.	Janssen Research and Development
23395660	48	Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.	Sanofi-Aventis Deutschland
23265904	54	Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).	Merck Research Laboratories
21661758	39	Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.	Merck Frosst Centre For Therapeutic Research
22101133	26	Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.	Merck Frosst Centre For Therapeutic Research
22047692	50	Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.	Merck Frosst Centre For Therapeutic Research
22209206	35	Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.	Merck Frosst Centre For Therapeutic Research
21924609	28	Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.	Merck Frosst Centre For Therapeutic Research
21871798	39	Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.	Merck Frosst Centre For Therapeutic Research
21324691	24	N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.	Pfizer
20933412	83	2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.	Merck Frosst Centre For Therapeutic Research
20137926	43	SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.	Merck Frosst Centre For Therapeutic Research
20004097	36	Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).	Merck Frosst Centre For Therapeutic Research
19632834	16	Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.	Merck Frosst Centre For Therapeutic Research
19577469	30	Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.	Gilead Sciences
19394219	40	Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.	Cv Therapeutics
27660693	11	T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.	Takeda Pharmaceutical
30248655	64	Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.	Japan Tobacco